Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

Dieuwertje E. Kok*, Maaike M.G.A. van den Berg, Liesbeth Posthuma, Iris van ’t Erve, Fränzel J.B. van Duijnhoven, Wilfred K. de Roos, Sissi Grosfeld, Maartje Los, Dirkje W. Sommeijer, Hanneke W.M. van Laarhoven, Renate M. Winkels, Ellen Kampman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D3 levels after chemotherapy. We reported lower 25(OH)D3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

Original languageEnglish
Pages (from-to)756-766
JournalNutrition and Cancer
Volume71
Issue number5
Early online date19 Jan 2019
DOIs
Publication statusPublished - May 2019

Fingerprint

Calcifediol
Breast Neoplasms
Drug Therapy
Confidence Intervals
Neoplasms
Vulnerable Populations
Dietary Supplements
Vitamin D
Life Style
Linear Models

Cite this

Kok, Dieuwertje E. ; van den Berg, Maaike M.G.A. ; Posthuma, Liesbeth ; van ’t Erve, Iris ; van Duijnhoven, Fränzel J.B. ; de Roos, Wilfred K. ; Grosfeld, Sissi ; Los, Maartje ; Sommeijer, Dirkje W. ; van Laarhoven, Hanneke W.M. ; Winkels, Renate M. ; Kampman, Ellen. / Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy. In: Nutrition and Cancer. 2019 ; Vol. 71, No. 5. pp. 756-766.
@article{928f41a3024c4e1a850edae4f0178189,
title = "Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy",
abstract = "Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95{\%} confidence interval (95{\%}CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95{\%}CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1 nmol/L, 95{\%}CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95{\%}CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D3 levels after chemotherapy. We reported lower 25(OH)D3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.",
author = "Kok, {Dieuwertje E.} and {van den Berg}, {Maaike M.G.A.} and Liesbeth Posthuma and {van ’t Erve}, Iris and {van Duijnhoven}, {Fr{\"a}nzel J.B.} and {de Roos}, {Wilfred K.} and Sissi Grosfeld and Maartje Los and Sommeijer, {Dirkje W.} and {van Laarhoven}, {Hanneke W.M.} and Winkels, {Renate M.} and Ellen Kampman",
year = "2019",
month = "5",
doi = "10.1080/01635581.2018.1559938",
language = "English",
volume = "71",
pages = "756--766",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Taylor & Francis",
number = "5",

}

Kok, DE, van den Berg, MMGA, Posthuma, L, van ’t Erve, I, van Duijnhoven, FJB, de Roos, WK, Grosfeld, S, Los, M, Sommeijer, DW, van Laarhoven, HWM, Winkels, RM & Kampman, E 2019, 'Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy', Nutrition and Cancer, vol. 71, no. 5, pp. 756-766. https://doi.org/10.1080/01635581.2018.1559938

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy. / Kok, Dieuwertje E.; van den Berg, Maaike M.G.A.; Posthuma, Liesbeth; van ’t Erve, Iris; van Duijnhoven, Fränzel J.B.; de Roos, Wilfred K.; Grosfeld, Sissi; Los, Maartje; Sommeijer, Dirkje W.; van Laarhoven, Hanneke W.M.; Winkels, Renate M.; Kampman, Ellen.

In: Nutrition and Cancer, Vol. 71, No. 5, 05.2019, p. 756-766.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

AU - Kok, Dieuwertje E.

AU - van den Berg, Maaike M.G.A.

AU - Posthuma, Liesbeth

AU - van ’t Erve, Iris

AU - van Duijnhoven, Fränzel J.B.

AU - de Roos, Wilfred K.

AU - Grosfeld, Sissi

AU - Los, Maartje

AU - Sommeijer, Dirkje W.

AU - van Laarhoven, Hanneke W.M.

AU - Winkels, Renate M.

AU - Kampman, Ellen

PY - 2019/5

Y1 - 2019/5

N2 - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D3 levels after chemotherapy. We reported lower 25(OH)D3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

AB - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D3 levels after chemotherapy. We reported lower 25(OH)D3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

U2 - 10.1080/01635581.2018.1559938

DO - 10.1080/01635581.2018.1559938

M3 - Article

VL - 71

SP - 756

EP - 766

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 5

ER -